The following stories appear in full on today's Vidyya Medical News Service Web site.
Last year, the Food and Drug Administration approved a large number of drugs, biological products and medical devices, many of which represent a impressive advance in the prevention, diagnosis and treatment for serious and life-threatening diseases. Groups that particularly benefit from the 160 approved medications and medical devices include patients with cancer, children, women, patients with heart disease and the elderly.
For more information: Report On New Health Care Products Approved In 2000
Although methylphenidate (Ritalin) is the most frequently prescribed drug for treating attention deficit hyperactivity disorder (ADHD), its mechanism of action and its effects on the human brain have been poorly understood. In an article in the January 12 online issue of the Journal of Neuroscience, researchers have for the first time assessed the effects of therapeutic doses of oral Ritalin on the levels of dopamine in the human brain. Dopamine imbalances appear to be closely related to ADHD symptoms.
For more information: New Research Expands Understanding Of Treatment For ADHD
Whether or not patients with very small breast tumors (those of one centimeter or less) need chemotherapy or hormonal therapy after surgery is a matter of debate among breast cancer experts. Now, a new look at five earlier studies suggests that post-surgical, or adjuvant, treatment should be considered as a treatment option.
For more information: Post-Surgical Therapy May Benefit Patients With Small Breast Tumors
Transplants of peripheral blood cells may be more effective than bone marrow transplants in patients who receive high-dose chemotherapy for blood cancer, according to a large randomized trial reported in the New England Journal of Medicine on 18 January 2001.
For more information: Blood Cancer Transplants: Peripheral Blood Cells Better Than Bone Marrow?
In the early 1990s, breast cancer advocates like Deborah Collyar spent much of their time demanding attention. "We made a lot of noise," said Collyar, who is now president of Patient Advocates In Research, a national organization based in San Francisco, Calif. As one of the early cancer advocates, Collyar was also persistent. She called investigators, wrote letters, demanded audiences, attended meetings and stood in line at the microphone when speakers invited questions. She, and other advocates like her, want a say in how breast cancer funds are spent.
For more information: Cancer Advocates In Research: The Movement Evolves
Today's Vidyya articles are:
As always, we hope you enjoy the issue.